Date: 2016-12-05
Type of
information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in Cancer Immunology, Immunotherapy
Company: Curevac (Germany)
Product: RNAdjuvant® Technology
Action
mechanism:
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On December 5, 2016, CureVac announced that a study with its RNAdjuvant® technology was published in the peer-reviewed journal Cancer Immunology, Immunotherapy. The study, titled “Immunological effects of a novel RNA-based adjuvant in liver cancer patients,” by Circelli et al., demonstrated for the first time ever that the company’s RNAdjuvant® to be used in a therapeutic cancer vaccine formulation is equally effective on peripheral blood mononuclear cells (PBMCs) from both healthy and hepatocellular carcinoma (HCC) patients. The data were collected in connection with the HEPAVAC project, which is sponsored by the EU.
- The study examined the effects of CureVac’s RNAdjuvant® technology on PBMCs obtained from eight healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. Treatment with RNAdjuvant® elicited comparable effects on PBMCs of both HCC and healthy subjects, having demonstrated up-regulation of several genes involved in innate and adaptive immune-related pathways.
Luigi Buonaguro, head of the HEPAVAC project, said, “The comparable immunomodulatory effects of RNAdjuvant® in HCC subjects and healthy subjects are extremely relevant in the field of vaccinology, in general, and for the HEPAVAC project, in specific. They strongly support the use of RNAdjuvant® in the HepaVac-101 vaccine formulation and are promising for a significant enhancement of the immunogenicity of the vaccine peptides in vivo.”
Is
general: Yes
